Reports Q1 revenue $52.28B, consensus $51.26B. “We began fiscal 2025 by delivering strong operational and financial performance, led by the Pharmaceutical and Specialty Solutions segment,” said Jason Hollar, CEO of Cardinal Health (CAH). “The strength and resiliency of our largest and most significant business continues to shine, giving us confidence to raise our fiscal 2025 enterprise guidance only a quarter into the year. Across the business, we remain focused on executing our plan to best serve our customers and create value for our shareholders.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Notable companies reporting before tomorrow’s open
- CAH Earnings this Week: How Will it Perform?
- Cardinal Health added to ‘Tactical Outperform’ list at Evercore ISI
- T2 Biosystems enters exclusive U.S. agreement with Cardinal Health
- Cardinal Health to acquire Integrated Oncology Network for $1.115B in cash